Feb 26, 2024 7:00am EST 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
Dec 04, 2023 9:00am EST 180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
Aug 07, 2023 9:00am EDT 180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
Aug 03, 2023 8:00am EDT 180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
Jul 31, 2023 8:00am EDT 180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
Apr 10, 2023 4:30pm EDT 180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
Apr 05, 2023 1:00pm EDT 180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement